We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

93 hedge funds and large institutions have $925M invested in Arcutis Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

345% more call options, than puts

Call options by funds: $1.38M | Put options by funds: $311K

111% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 19

1.23% more ownership

Funds ownership: 90.96% → 92.19% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

10% less funds holding

Funds holding: 103 → 93 (-10)

12% less capital invested

Capital invested by funds: $1.05B → $925M (-$130M)

43% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 21

Holders
93
Holders Change
-10
Holders Change %
-9.71%
% of All Funds
1.43%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
40
Reduced
19
Closed
21
Calls
$1.38M
Puts
$311K
Net Calls
+$1.07M
Net Calls Change
+$280K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13M
2
LGM
Logos Global Management
California
+$4.98M
3
PCH
Polar Capital Holdings
United Kingdom
+$4.68M
4
Norges Bank
Norges Bank
Norway
+$4.07M
5
BlackRock
BlackRock
New York
+$2.35M

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$12.6M
2
VC
Vivo Capital
California
-$10.4M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$10.3M
4
ACM
Altium Capital Management
New York
-$6.09M
5
Ameriprise
Ameriprise
Minnesota
-$2.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$2.94M -$12.6M -631,652 -82%
PVI
27
Pura Vida Investments
New York
$2.88M +$524K +26,339 +23%
TCM
28
Tekla Capital Management
Massachusetts
$2.73M – – –
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$2.57M +$886K +44,511 +56%
Neuberger Berman Group
30
Neuberger Berman Group
New York
$2.53M +$199 +10 +0%
Citigroup
31
Citigroup
New York
$2.49M +$1.9M +95,304 +382%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$2.02M +$48.9K +2,459 +3%
Walleye Capital
33
Walleye Capital
New York
$1.73M +$1.66M +83,420 New
HWAM
34
Hennion & Walsh Asset Management
New Jersey
$1.35M +$692K +34,752 +114%
AA
35
ALPS Advisors
Colorado
$1.21M -$67.2K -3,375 -5%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$1.18M +$530K +26,627 +88%
Swiss National Bank
37
Swiss National Bank
Switzerland
$1.15M – – –
UBS Group
38
UBS Group
Switzerland
$1.13M +$488K +24,508 +81%
Morgan Stanley
39
Morgan Stanley
New York
$1.1M -$1.81M -90,727 -63%
AA
40
AlphaCentric Advisors
Puerto Rico
$1.09M +$338K +17,000 +48%
HLA
41
Hamilton Lane Advisors
Pennsylvania
$1.09M – – –
Goldman Sachs
42
Goldman Sachs
New York
$1M +$151K +7,607 +19%
HSBC Holdings
43
HSBC Holdings
United Kingdom
$810K +$687K +34,523 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$752K +$14.9K +750 +2%
TD Asset Management
45
TD Asset Management
Ontario, Canada
$745K +$108K +5,410 +18%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$738K +$358 +18 +0.1%
UBS AM
47
UBS AM
Illinois
$622K – – –
Los Angeles Capital Management
48
Los Angeles Capital Management
California
$580K +$139 +7 +0%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$525K – – –
Blackstone Inc
50
Blackstone Inc
New York
$501K – – –
1
2
3 4 5

ARQT Hedge Fund Activity: Q4 2021 in Review

93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2021, worth a combined $925M — down 12% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ARQT and 12 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 40 added.

The largest buyer was Point72 Asset Management, adding an estimated $13M. The largest seller was Wells Fargo, cutting an estimated $12.6M.

  • 93 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2021, down from 103 in Q3 2021.
  • Funds reported $925M of Arcutis Biotherapeutics stock for Q4 2021, down 12% quarter-over-quarter.
  • 12 funds opened new Arcutis Biotherapeutics positions in Q4 2021 and 21 closed out, a net change of -9 holders.
  • The largest Arcutis Biotherapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $13M added.
  • The largest Arcutis Biotherapeutics seller in Q4 2021 was Wells Fargo, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2021.